[1]OrganicandBiomolecularChemistry,2015,vol.13,p.5147-5157
[2]Patent:WO2017/39425,2017,A1.Locationinpatent:Page/Pagecolumn7;8
[3]Patent:CN105622613,2016,A.Locationinpatent:Paragraph0109;0204;0205;0206;0207
[4]Patent:WO2017/137446,2017,A1.Locationinpatent:Page/Pagecolumn15
[5]Patent:CN104557945,2017,B.Locationinpatent:Paragraph0070;0071;0072;0074;0075
[6]Patent:WO2014/139970,2014,A1.Locationinpatent:Page/Pagecolumn19;25
[7]Patent:CN106146511,2016,A.Locationinpatent:Paragraph0153;0154;0155
[8]Patent:CN105399756,2016,A.Locationinpatent:Paragraph0155;0174-0176
[9]Patent:CN106188062,2016,A.Locationinpatent:Paragraph0082;0083;0084;0085;0086;0087
[10]Patent:US2008/214501,2008,A1.Locationinpatent:Page/Pagecolumn12
[11]Patent:WO2012/158795,2012,A1.Locationinpatent:Page/Pagecolumn77
[12]Patent:WO2013/191965,2013,A1.Locationinpatent:Page/Pagecolumn157
[13]Patent:WO2014/22569,2014,A1.Locationinpatent:Page/Pagecolumn50
[14]Patent:US8673925,2014,B1.Locationinpatent:Page/Pagecolumn201
[15]JournalofMedicinalChemistry,2015,vol.58,p.9625-9638
[16]Patent:WO2017/163257,2017,A1.Locationinpatent:Page/Pagecolumn19
[17]Patent:CN106008526,2016,A.Locationinpatent:Paragraph0016;0063;0064;0065
[18]Patent:CN109232581,2019,A.Locationinpatent:Paragraph0014
[1]Patent:US2008/214501,2008,A1.Locationinpatent:Page/Pagecolumn13
[1]Patent:WO2012/158795,2012,A1
[2]Patent:WO2013/191965,2013,A1
[3]Patent:WO2013/191965,2013,A1
[4]Patent:WO2014/22569,2014,A1
[5]Patent:WO2014/22569,2014,A1
[6]Patent:US8673925,2014,B1
[7]Patent:US8673925,2014,B1
[8]Patent:WO2014/176348,2014,A1
[9]OrganicandBiomolecularChemistry,2015,vol.13,p.5147-5157
[10]JournalofMedicinalChemistry,2015,vol.58,p.9625-9638
[11]Patent:CN105859728,2016,A
[12]Patent:CN105399756,2016,A
[13]Patent:CN106146511,2016,A
[14]Patent:CN104557945,2017,B
[1]Patent:WO2012/158795,2012,A1
[2]Patent:WO2013/191965,2013,A1
[3]Patent:WO2013/191965,2013,A1
[4]Patent:WO2014/22569,2014,A1
[5]Patent:WO2014/22569,2014,A1
[6]Patent:US8673925,2014,B1
[7]Patent:US8673925,2014,B1
[8]Patent:WO2014/176348,2014,A1
[9]OrganicandBiomolecularChemistry,2015,vol.13,p.5147-5157
[10]JournalofMedicinalChemistry,2015,vol.58,p.9625-9638
[11]Patent:CN105859728,2016,A
[12]Patent:CN105399756,2016,A
[13]Patent:CN104557945,2017,B
[14]Patent:CN109111446,2019,A
[1]Patent:WO2012/158795,2012,A1
[2]Patent:WO2013/191965,2013,A1
[3]Patent:WO2014/22569,2014,A1
[4]Patent:US8673925,2014,B1
[5]Patent:CN106146511,2016,A
[6]Patent:CN104557945,2017,B
Title: Somana Siva Prasad, et al. A QUALITY BY DESIGN APPROACH FOR DEVELOPMENT OF SIMPLE AND ROBUST REVERSED PHASE STABILITY INDICATING HPLC METHOD FOR ESTIMATION OF IBRUTINIB AND ITS IMPURITIES.
Title: Honigberg LA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80.
Title: Liu N, et al. Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study. Org Biomol Chem. 2015 May 14;13(18):5147-57.